Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + gaboxadol
- Development stage
- Discontinued
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of escitalopram, a selective serotonin reuptake inhibitor (SSRI), and gaboxadol, a selective extrasynaptic GABA receptor agonist. This combination was investigated for the treatment of major depressive disorder (MDD). Escitalopram works by inhibiting serotonin reuptake in the presynaptic neuron, while gaboxadol acts as a direct and selective agonist of extrasynaptic GABAA receptors, particularly those containing the delta subunit.
02
Targets
SERT (Sodium-dependent serotonin transporter)GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on escitalopram + gaboxadol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + gaboxadol.